Der Test einer Laborprobe. (Symbolbild)
Freitag, 05.03.2021 18:45 von | Aufrufe: 69

SHAREHOLDER ALERT: WeissLaw LLP Reminds BFTL, ALXN, STPK, and BRPA Shareholders About Its Ongoing Investigations

Der Test einer Laborprobe. (Symbolbild) © alvarez / E+ / Getty Images http://www.gettyimages.de

PR Newswire

NEW YORK, March 5, 2021 /PRNewswire/ --

If you own shares in any of the companies listed above and would like to discuss our investigations or have any questions concerning this notice or your rights or interests, please contact:

Joshua Rubin, Esq.
WeissLaw LLP
1500 Broadway, 16th Floor
New York, NY  10036
(212) 682-3025
(888) 593-4771
stockinfo@weisslawllp.com

Bank of Fincastle (OTCM: BFTL)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Bank of Fincastle (OTCM: BFTL) in connection with the proposed acquisition of the company by First National Corporation (First National).  Under the terms of the merger agreement, BFTL shareholders may elect to receive either $3.30 in cash, 0.1649 shares of First National common stock, or a combination of cash and First National stock for each share of BFTL that they own.  If you own BFTL shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website:  https://www.weisslawllp.com/bftl/

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) in connection with the proposed acquisition of the company by AstraZeneca PLC ("AstraZeneca").  Under the terms of the agreement, ALXN shareholders will receive $60.00 and 2.1243 AstraZeneca American Depositary Shares ("ADS") (each ADS representing one-half of one ordinary share of AstraZeneca) for each share of ALXN they hold.  If you own ALXN shares and wish to discuss this investigation or your rights, please call us or visit our website:  https://weisslawllp.com/alxn/

Star Peak Energy Transition Corp. (NYSE: STPK)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Star Peak Energy Transition Corp. (NYSE: STPK) in connection with the company's proposed merger with privately held Stem, Inc. ("Stem").  Under the terms of the merger agreement, STPK will acquire Stem through a reverse merger that will result in Stem becoming a publicly traded company.  If you own STPK shares and wish to discuss this investigation or your rights, please call us at one of the numbers listed above or visit our website: https://weisslawllp.com/stpk/


ARIVA.DE Börsen-Geflüster

Big Rock Partners Acquisition Corp. (NASDAQ: BRPA)
WeissLaw LLP is investigating possible breaches of fiduciary duty and other violations of law by the board of directors of Big Rock Partners Acquisition Corp. (NASDAQ: BRPA) in connection with the company's proposed merger with privately held NeuroRx, Inc. ("NeuroRx").  Under the terms of the merger agreement, BRPA will acquire NeuroRx through a reverse merger, with NeuroRx surviving as a publicly traded company.  If you own BRPA shares and wish to discuss this investigation or your rights, please call us or visit our website: https://weisslawllp.com/brpa/

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/shareholder-alert-weisslaw-llp-reminds-bftl-alxn-stpk-and-brpa-shareholders-about-its-ongoing-investigations-301241740.html

SOURCE WeissLaw LLP

Werbung

Mehr Nachrichten zur Alexion Pharmaceuticals Aktie kostenlos abonnieren

E-Mail-Adresse
Benachrichtigungen von ARIVA.DE
(Mit der Bestellung akzeptierst du die Datenschutzhinweise)

Hinweis: ARIVA.DE veröffentlicht in dieser Rubrik Analysen, Kolumnen und Nachrichten aus verschiedenen Quellen. Die ARIVA.DE AG ist nicht verantwortlich für Inhalte, die erkennbar von Dritten in den „News“-Bereich dieser Webseite eingestellt worden sind, und macht sich diese nicht zu Eigen. Diese Inhalte sind insbesondere durch eine entsprechende „von“-Kennzeichnung unterhalb der Artikelüberschrift und/oder durch den Link „Um den vollständigen Artikel zu lesen, klicken Sie bitte hier.“ erkennbar; verantwortlich für diese Inhalte ist allein der genannte Dritte.